Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (47)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Clinical presentation, microbiology, and prognostic factors of prosthetic valve endocarditis. Lessons learned from a large prospective registry

    PloS one, Vol. 18, Núm. 9, pp. e0290998

  3. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial

    Nature Medicine, Vol. 29, Núm. 10, pp. 2518-2525

  4. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

  5. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae

    American Journal of Transplantation, Vol. 23, Núm. 7, pp. 1022-1034

  6. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  7. Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 77, Núm. 9, pp. 1273-1281

  8. Impact of SARS-CoV-2 RNAemia and other risk factors on long-COVID: A prospective observational multicentre cohort study

    Journal of Infection

  9. Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice

    Transplantation, Vol. 107, Núm. 3, pp. 762-773

  10. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

    The Lancet, Vol. 401, Núm. 10370, pp. 49-59